MT1G Hypermethylation: A Potential Prognostic Marker for Hepatoblastoma

Autor(es)

Sakamoto, Luis H. T. ^[1] ; de Camargo, Beatriz ^[2] ; Cajaiba, Mariana ^[3] ; Soares, Fernando A. ^[3] ; Vettore, Andre L. ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Ludwig Inst Canc Res, Sao Paulo Branch, BR-01323903 Sao Paulo - Brazil

^[2] AC Camargo Hosp, Dept Pediat, BR-01509010 Sao Paulo - Brazil

^[3] AC Camargo Hosp, Dept Pathol, BR-01509010 Sao Paulo - Brazil

^[4] Univ Fed Sao Paulo, Dept Ciencias Biol, Canc Genet Lab, BR-04039032 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Pediatric Research; v. 67, n. 4, p. 387-393, APR 2010.
• Citações Web of Science: 24

Resumo

Hepatoblastoma comprises only 1% of all cancers in childhood. Because of its low frequency, a small number of prognostic factors are described in hepatoblastoma and most of them are related to resectability. Microarray Studies showed a large number of underexpressed genes in hepatoblastoma. Because aberrant DNA methylation has been recognized as an alternative mechanism for tumor suppressor gene inactivation, this could be involved with gene downregulation in these tumors. Despite the rarity of hepatoblastoma, this study evaluated the methylation pattern of 25 genes in 20 paraffin-embedded tumor specimens and five non-neoplastic liver samples (normal control) by quantitative methylation-specific PCR (QMSP). The examination of the methylation profile of hepatoblastoma samples and normal liver specimens revealed a high tumorspecific DNA hypermethylation in the promoter regions of five genes (APC, CDH1, MT1G, RASSF1A, and SOCS1). Furthermore, MT1G hypermethylation showed a significant correlation with poor prognosis of patients with hepatoblastoma. This study represents the first quantitative evaluation of promoter hypermethylation in hepatoblastoma and demonstrated that aberrant methylation is a frequent event in this malignancy. Furthermore, our data provide evidence that MT1G hypermethylation may be useful as prognostic indicator for this disease and suggest that patients with hepatoblastoma may benefit from demethylating drug treatments. (Pediatr Res 67: 387-393, 2010) (AU)

• Processo FAPESP: 06/61572-8 - Identificacao de novos marcadores de prognostico para dois tipos de cancer: mieloma multiplo e hepatoblastoma.
• Beneficiário: Andre Luiz Vettore de Oliveira
• Modalidade de apoio: Auxílio à Pesquisa - Regular